Table 1. Demographic and clinical characteristics of HIV+ subjects in the study cohort.
| Age (years) | |
| Mean ± SD | 45±7.3 |
| Median (range) | 44 (32–63) |
| Gender | |
| Male | 43 (75%) |
| Female | 14 (25%) |
| Race | |
| African American | 25 (44%) |
| Caucasian | 15 (26%) |
| Hispanic | 14 (25%) |
| Other | 3 (5%) |
| Risk factor | |
| Sexual transmission | 17 (30%) |
| Intravenous drug abuse | 40 (70%) |
| CD4 T cell count (cells/µl) | |
| Mean ± SD | 122±126 |
| Median (range) | 81 (3–688) |
| CD4 nadir T cell count (cells/µl) | |
| Mean ± SD | 82±69.1 |
| Median (range) | 61 (1–261) |
| Plasma HIV RNA (copies/ml) | |
| Mean ± SD | 131,365±408,505 |
| Median (range) | 2460 (<50–2,210,000) |
| <400 copies/ml | 22 (38%) |
| cART | |
| Yes | 52 (91%) |
| No | 5 (9%) |
| HCV co-infection | |
| Positive | 27 (47%) |
| Negative | 18 (32%) |
| Unknown | 12 (21%) |
| Substance abuse | |
| Opiates* | 22 (38%) |
| Cocaine* | 32 (55%) |
| None | 17 (30%) |
(n = 57).
*14 subjects used both opiate and cocaine based on self-report or urine toxicology at time of plasma sampling.